Fuchs eye disease, formally called Fuchs endothelial corneal dystrophy, is a progressive condition in which cells on the inner surface of the cornea gradually die off, causing the cornea to swell with fluid and vision to blur. It affects up to 7% of adults worldwide, with the average age at diagnosis around 62 years old. The disease typically begins silently in a person’s 30s or 40s and progresses slowly over 20 to 30 years, meaning many people live with early-stage Fuchs for decades before noticing any symptoms.
How the Cornea Normally Works
Your cornea is the clear, dome-shaped window at the front of your eye. Its inner lining is a single layer of cells called endothelial cells, and their job is to pump excess fluid out of the cornea to keep it thin and transparent. A healthy cornea maintains roughly 60% hexagonal cells in this layer, packed tightly together like tiles. In Fuchs disease, these cells deteriorate faster than normal. Unlike most cells in your body, corneal endothelial cells don’t regenerate. Once they’re gone, the remaining cells stretch to cover the gaps, but eventually they can’t keep up. Fluid seeps into the cornea, it swells, and your vision clouds.
What Causes It
Fuchs disease runs in families with an autosomal dominant inheritance pattern, meaning you only need to inherit one copy of the affected gene from one parent to be at risk. The most significant genetic factor is an expansion of a repeating DNA sequence in a gene called TCF4. In one study, 79% of people with confirmed Fuchs disease carried this expanded repeat, compared to just 3% of people without the condition. Carrying one copy of the most strongly associated genetic variant raises your risk about 5.5 times; carrying two copies raises it 30-fold.
Researchers have also identified variants in several other genes that contribute to risk, though TCF4 remains by far the most common culprit. Fuchs is actually considered the most common trinucleotide repeat expansion disease in humans. The late-onset form, which accounts for the vast majority of cases, tends to show variable severity even within the same family, so two siblings who inherit the same gene variant may experience very different levels of vision loss.
The Hallmark Symptom: Morning Blur
The most distinctive early symptom is blurred vision that’s worst when you wake up and gradually clears as the day goes on. This happens because your eyelids are closed overnight, trapping moisture against the cornea. A healthy cornea handles this fine, but a Fuchs-affected cornea is already waterlogged, and the extra overnight hydration pushes it past its limit. Once your eyes are open, evaporation from the tear film helps draw fluid out, and vision improves. As the disease advances, that clearing takes longer each morning, and eventually the blur may not clear at all.
Other symptoms include glare and halos around lights (especially at night), a hazy or foggy quality to vision, and a fluctuating prescription. Some people find themselves switching between multiple pairs of glasses throughout the day as their corneal thickness shifts and their focus changes.
Four Stages of Progression
Fuchs disease progresses through four recognized stages, though many people never reach the later ones.
Stage 1 produces no symptoms. Small bumps called guttae form on the back surface of the cornea where endothelial cells are lost, but the remaining cells compensate well enough that you won’t notice anything. This stage is often discovered incidentally during a routine eye exam. It’s indistinguishable from harmless corneal guttae that many older adults develop, and it’s only recognized as Fuchs in retrospect once the disease progresses.
Stage 2 is when the cornea begins to swell and symptoms appear. Painless blurry vision and glare are the main complaints, worse in the morning. The cornea looks hazy on examination, and night vision deteriorates. Some people notice discomfort while blinking.
Stage 3 brings fluid-filled blisters, called bullae, on the cornea’s outer surface. These tiny blisters can rupture, causing episodes of sharp pain and leaving the eye vulnerable to infection. Vision worsens significantly.
Stage 4 is the most advanced. Scar tissue forms across the cornea and new blood vessels may grow into it. Vision can drop to the point where you can only detect hand movements. Paradoxically, the scarring may reduce pain because the nerve-rich outer layers are replaced by less sensitive tissue.
How It’s Diagnosed
An eye doctor can spot Fuchs disease during a standard slit-lamp exam by looking for the characteristic guttae on the back of the cornea. To assess severity, two additional measurements help. Specular microscopy photographs the endothelial cell layer and counts how many cells remain per square millimeter. A cell density below 1,000 cells per square millimeter signals significant loss. The microscope also reveals whether the remaining cells have become irregular in size and shape, both signs of stress.
Corneal thickness measurements (pachymetry) provide another objective marker. In Fuchs disease, the center of the cornea swells more than the edges, so the ratio of central-to-peripheral thickness increases as the disease worsens. This ratio correlates closely with clinical severity and helps track progression over time.
Managing Mild to Moderate Disease
In the earlier stages, treatment focuses on reducing corneal swelling without surgery. Hypertonic (extra-salty) eye drops or ointments draw fluid out of the cornea through osmosis. These are typically applied four times daily. The ointment form, at 6% concentration, tends to be more effective than standard 5% drops. Many people use the ointment at bedtime to counteract overnight swelling and the drops during the day.
Other practical strategies include using a hair dryer held at arm’s length on a cool or warm setting to gently blow air across your eyes in the morning, speeding up evaporation and clearing the morning blur faster. Avoiding humid environments when possible can also help.
When Surgery Becomes Necessary
When drops and ointments no longer control symptoms, corneal transplant surgery is the definitive treatment. Modern techniques don’t replace the entire cornea. Instead, surgeons selectively replace only the damaged inner layer. The two main approaches are DSAEK and DMEK, both of which involve peeling away the diseased endothelial layer and attaching healthy donor tissue in its place.
DMEK transplants a thinner graft (just the endothelial cells and their basement membrane) and produces better visual outcomes. In a comparative study of Fuchs patients, those who received DMEK gained an average of 3.3 lines on the eye chart, while DSAEK patients gained 1.3 lines. DMEK patients were more likely to achieve 20/20 vision. However, DMEK is technically more demanding for the surgeon, and DSAEK remains a reliable option, particularly for eyes with complicating factors.
Recovery from either procedure is relatively quick compared to traditional full-thickness corneal transplants. You’ll spend the first day or two lying face-up to help the graft adhere, and most people see meaningful improvement within the first few months. Because these procedures use donor tissue, you’ll need to use anti-rejection eye drops for an extended period afterward.
Newer Approaches on the Horizon
A class of eye drops called ROCK inhibitors, originally developed for glaucoma, has shown promise in helping corneal endothelial cells recover in early-stage Fuchs disease. In one approach, surgeons strip away the guttae-covered central portion of the inner corneal layer (a procedure called Descemet stripping only) and then apply ROCK inhibitor drops to encourage the remaining healthy cells to migrate and repopulate the area. This avoids the need for donor tissue entirely.
These drops are not yet approved specifically for Fuchs disease in any country, and no standardized pharmacological treatment for the condition has received regulatory approval. But early clinical results are encouraging enough that some ophthalmologists use them off-label, particularly for patients with acute endothelial cell loss or early-stage disease where the remaining cell population may still be capable of recovery.